Instrument Inactif

Communiqués MaxCyte, Inc. London S.E.

Actions

MXCN

USU575801258

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MaxCyte, Inc. - Grant of Options and Restricted Stock Units	17/06	AQ
MaxCyte, Inc. - Results of AGM	13/06	AQ
MaxCyte, Inc. - PDMR Dealing	12/06	AQ
MaxCyte : Participation in Upcoming Investor Conference	29/05	PU
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference	29/05	GL
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	22/05	GL
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	09/05	AQ
MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024	09/05	AQ
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	07/05	GL
MaxCyte, Inc. - Notice of AGM	06/05	AQ
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024	10/04	GL
MaxCyte, Inc. - Exercise of options and PDMR dealing	03/04	AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B cell Medicines	03/04	AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)	02/04	GL
MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing	21/03	AQ
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance	12/03	GL
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	06/03	AQ
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	04/03	GL
MaxCyte, Inc. - Exercise of options and PDMR dealing	01/03	AQ
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences	09/02	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués MaxCyte, Inc. London S.E.

Actions

MXCN

USU575801258

Communiqués

Filtres